Slide 1: Full-year and Q4 2021 results
Full-year and Q4 2021 results March 2022 Roadshow
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: This slide is intentionally blank
This slide is intentionally blank 3
Slide 4: Agenda
1 Opening remarks Agenda 2 Financial results 3 Oncology BioPharmaceuticals, 4 Emerging Markets 5 Rare Disease 6 Closing remarks and Q&A 4
Slide 5: Opening remarks
1 Opening remarks Pascal Soriot Chief Executive Officer 5
Slide 6: Full year and Q4 2021: key updates
Full year and Q4 2021: key updates Continuing to deliver on our strategic objectives Robust growth Broad-based performance Science-led innovation Exceeded FY 2021 revenue guidance Delivering value to patients Strong Q4 2021 performance • Total Revenue $37.4bn (+38%) • Oncology $13.7bn (+17%) • Tezsp
Slide 7: Full year and Q4 2021: performance
Full year and Q4 2021: performance Oncology, CVRM, R&I and Rare Disease all delivered strong growth Growth Growth across disease areas across geographies (excluding Vaxzevria) CER CER CER CER FY 2021 Q4 2021 FY 2021 Q4 2021 growth growth growth growth $m $m $m $m % % % % 13,663 17 3,919 21 US 12,164
Slide 8: AstraZeneca: 2022-2025
AstraZeneca: 2022-2025 Industry leading double-digit growth Durable growth drivers through 2025 Diversification including multiple blockbuster-medicines of disease areas and geographies Q4 2021 Total Revenue1 Rare Oncology CVRM R&I V&I Disease Other 9% Est. RoW 13% Rare Oncology US 17% 38% Europe 38
Slide 9: AstraZeneca: 2025+
AstraZeneca: 2025+ Delivering growth through innovation Robust life-cycle Innovative Strategic business Attractive management late-stage pipeline development LoE profile Supports durable, Continued investment in Recent clinical stage US LoE for growing revenue base clinical stage pipeline business d
Slide 10: Late-stage pipeline delivery
Late-stage pipeline delivery Important milestones since Q3 2021 update Medicine Indication / Event Geography Regulatory Saphnelo systemic lupus erythematosus: CHMP positive opinion EU approvals or Tezspire severe asthma US other regulatory action Evusheld COVID-19 prophylaxis: emergency use authoris
Slide 11: Reported profit and loss
Reported profit and loss FY 2021 CER change % total Q4 2021 CER change % total $m % revenue $m % revenue Total Revenue 37,417 38 100 12,011 63 100 - Product Sales 36,541 38 98 11,498 65 96 - Collaboration Revenue 876 20 2 513 29 4 Gross margin 66.0% (12.6) pp 59.8% (16.0) pp Operating expenses1 25,4
Slide 12: Core profit and loss
Core profit and loss Core EPS above FY 2021 guidance FY 2021 CER change % total Q4 2021 CER change % total $m % revenue $m % revenue Total Revenue 37,417 38 100 12,011 63 100 - Product Sales 36,541 38 98 11,498 65 96 - Collaboration Revenue 876 20 2 513 29 4 Gross margin 74.2% (4.7) pp 74.3% (1.9) p
Slide 13: 2022 Guidance
2022 Guidance Continuing to drive innovation and growth Total revenue guidance Core EPS guidance Headwinds Tailwinds • Ongoing pricing pressure in China, Grow by high-teens % Grow by mid-to-high twenties % • First full year of Alexion ownership mid single-digit revenue decline $Bn $ anticipated 45 •
Slide 14: Financial results
2 Financial results Aradhana Sarin Chief Financial Officer
Slide 15: Net debt and capital allocation priorities
Net debt and capital allocation priorities FY 2021 dividend increased to $2.87 (intended annualised dividend increase of $0.10) Net debt Capital allocation priorities Net debt: $24,322m; EBITDA1: $7,586m $bn • Strong investment grade credit rating • Reinvestment in the business • Value-enhancing bus
Slide 16: Oncology
3 Oncology Dave Fredrickson EVP Oncology Business Susan Galbraith EVP Oncology R&D
Slide 17: Tagrisso and Imfinzi
Tagrisso and Imfinzi Increased reimbursement and launches offsetting COVID-19 impact on diagnosis Tagrisso: 13% growth to $5.0bn Imfinzi: 16% growth to $2.4bn Approvals/Reimbursements: 69/19 (adjuvant), 92/52 (1L), 92/68 (2L) Approvals/Reimbursements: 75/35 (NSCLC), 67/9 (ES-SCLC) $m $m 1,400 • US +
Slide 18: Lynparza
Lynparza The globally leading PARP inhibitor across four tumour types Product sales Growth in all regions Collaboration revenue1 30% growth to $2.3bn Approvals: 86 (OC), 84 (mBC), 70 (mCRPC) $3.5bn recorded, $4.2bn future potential $m $m 700 1,000 • US +24% 900 600 Growth driven by ovarian, prostate
Slide 19: Calquence and Enhertu
Calquence and Enhertu Strong launch trajectories continue Calquence: 136% growth to $1.2bn Enhertu: 123% growth to $214m Approvals/Reimbursements: 76/25 (CLL), 37/13 (MCL) Approvals/Reimbursements: 9/4 (mBC), 4/2 (GC) $m $m 450 • Global $1,238m; US $1,089m 80 • Global $214m; US $169m 400 • US CLL 70
Slide 20: Oncology: R&D pipeline highlights
Oncology: R&D pipeline highlights Strong congress presence; HIMALAYA and TOPAZ-1 support launch into GI cancers SABCS ASH ASCO GI Enhertu, Dato-DXd, Lynparza, Calquence Imfinzi, tremelimumab Imfinzi and camizestrant and capivasertib and Enhertu • TROPION-PanTumor01: promising • ASCEND: durable effic
Slide 21: BioPharmaceuticals, Emerging Markets
4 BioPharmaceuticals, Emerging Markets Ruud Dobber EVP, BioPharmaceuticals Business Mene Pangalos EVP, BioPharmaceuticals R&D
Slide 22: BioPharmaceuticals: Cardiovascular, Renal and Metabolism
BioPharmaceuticals: Cardiovascular, Renal and Metabolism Total Revenue $8.0bn; growth +9% Farxiga: 49% growth to $3.0bn Lokelma Strong momentum continues, fastest growing SGLT2i globally Global sales of $175m $m 100% US branded K+ binder TRx share1 900 90% 80% 800 70% • US +29%, Europe +52% and EM 6
Slide 23: BioPharmaceuticals: Respiratory and Immunology
BioPharmaceuticals: Respiratory and Immunology Total Revenue $6.0bn; growth +9% Fasenra Breztri Saphnelo 31% growth to $1.3bn COPD launch progressing; sales of $203m SLE launch progressing $m 400 • Positive early market response, despite T8 triple FDCs brand share (DOT)2 300 13% COVID-19 headwinds 2
Slide 24: Tezspire approved for severe asthma in the US
Tezspire approved for severe asthma in the US First and only biologic approved with no phenotype or biomarker limitation Addressing the unmet need Tezspire addresses the full spectrum in severe asthma of severe asthma patients c.2.5m Indicator Blood eosinophils (≥ 300 cells/µL) % Total Patient Popul
Slide 25: Emerging Markets
Emerging Markets Total revenue $12.3bn (including Vaxzevria1 revenue) Emerging markets +10%2 Diversified growth across geographies $m China +4%; Ex-China EMs +21%2 Launches in ex-China Emerging Markets progressing well 4,000 • Oncology $3.2bn, +6%: Tagrisso $1.3bn, up 6% continued 3,500 impact from
Slide 26: BioPharmaceuticals: R&D pipeline highlights
BioPharmaceuticals: R&D pipeline highlights Four NMEs approved in 2021: Saphnelo, Tezspire, Evusheld and Vaxzevria Evusheld Vaxzevria eplontersen Only long-acting antibody combination Clinical and real-world evidence ATTR shown to prevent and treat COVID-19 supports use as booster Collaboration with
Slide 27: Rare Disease
5 Rare Disease Marc Dunoyer Chief Executive Officer, Alexion
Slide 28: Rare Disease
Rare Disease Total Revenue $3.1bn; +9% pro rata1 FY 2021 Growth across all regions Rare Disease performance Pro rata growth, 20211 C5 Franchise (Soliris + Ultomiris) +11% Q4; +8% pro rata FY 20212; +9%1 • Soliris: double-digit volume growth in +8% 3,500 Neurology; Q4 benefitted from tender 2,000 3,0
Slide 29: Expanding beyond heart failure in amyloidosis
Expanding beyond heart failure in amyloidosis Cohesive commercial and development strategy across Cardiovascular and Rare Disease Leveraging strengths and expertise Complementary MOAs needed in ATTR across Cardiovascular, Rare Disease to address full spectrum of patient need Farxiga in Heart Failure
Slide 30: Investing in Rare Disease
Investing in Rare Disease Late-stage weighted pipeline, multiple long-term growth opportunities Robust late-stage pipeline Expanding & diversifying breadth of LCM and NME opportunities our Rare Disease portfolio; key events in Q4 • US FDA accepted Ultomiris in generalised myasthenia gravis for prior
Slide 31: Closing remarks and Q&A
6 Closing remarks and Q&A
Slide 32: Pipeline catalysts for 2022 - 2023
Pipeline catalysts for 2022 - 2023 Industry leading news flow Oncology BioPharmaceuticals Rare Disease H1 2022 H2 2022 2023 Regulatory Lynparza – breast cancer (adjuvant) (US) Tagrisso – EGFRm NSCLC (adjuvant) (JP) Enhertu – HER2+ breast cancer (2L) (US) Imfinzi +/- tremelimumab – NSCLC (1L) decisio
Slide 33: AstraZeneca: the next chapter
AstraZeneca: the next chapter Industry-leading growth, best-in-class innovative pipeline Double-digit CAGR Differentiated, Financial Reinvestment in our through 2025 durable portfolio execution main disease areas ` Longer-term growth Attractive LOE Continued focus High-growth pipeline fueled by exis
Slide 34: Q&A
Click to enter Q&A title Full-yearhere and Q4 2021 Results Speakers 34
Slide 35: Appendix
A Appendix
Slide 36: Scope 1+2 emissions reduction targets
Scope 1+2 emissions reduction targets Absolute Scope 1+2 emissions reduction targets Target ranking Target temperature Company Rank alignment (°C)2 AstraZeneca <1.1 1 Novo Nordisk <1.1 2 Takeda <1.1 3 Thousand tonnes tCO2e Sanofi 1.15 4 GSK Merck & Co 1.15 5 Pfizer Roche 1.24 6 Sanofi Johnson & John
Slide 37: Early pipeline news flow (1/2)
Early pipeline news flow (1/2) Next key milestone by project Oncology BioPharmaceuticals: CVRM Project Target Phase Indication Next milestone Project Target Phase Indication Next milestone GLP-1/ adavosertib WEE1 II uterine, pancreatic cancer Phase III start cotadutide II NASH Phase III start, H2 20
Slide 38: Early pipeline news flow (2/2)
Early pipeline news flow (2/2) Next key milestone by project BioPharmaceuticals: Respiratory and Immunology Rare Disease Project Target Phase Indication Next milestone Project Target Phase Indication Next milestone tozorakimab IL-33 II asthma Phase II data, H2 2022 ALXN1720 3rd-gen C5 I gMG Phase I
Slide 39: Commercial context: PROpel, HIMALAYA, TOPAZ-1 and DESTINY-Breast04
B Commercial context: PROpel, HIMALAYA, TOPAZ-1 and DESTINY-Breast04
Slide 40: PROpel
1 PROpel
Slide 41: Prostate is the second most common cancer in male patients
Prostate is the second most common cancer in male patients mCRPC therapies are limited; mostly monotherapy, including in first line Hormone sensitive Castration resistant Urologist-led Urologists and oncologists Urologists and oncologists Primary/ Biochemical mHSPC nm 1st-line metastatic 2nd-line+ m
Slide 42: PROpel - unprecedented clinical benefit without compromising quality of life
PROpel - unprecedented clinical benefit without compromising quality of life - a potential new SoC in mCRPC 300 Outcomes remain poor PROpel mg + abiraterone in advanced prostate cancer building on the success of PROfound a potential new standard of care 40% • Representative real-world population - •
Slide 43: PROpel: a new treatment approach in 1st-line mCRPC
PROpel: a new treatment approach in 1st-line mCRPC 1st-line metastatic castration-resistant prostate cancer (mCRPC) - US patients NHA naïve ~50% Prior NHA use ~50% Other (~25%) Receiving NHA ( ~75%) Receiving NHA ( ~55%) Other (~45%) HRRm 20-30% Overall, ~65% of 1st-line mCRPC patients receive an NH
Slide 44: HIMALAYA & TOPAZ-1
2 HIMALAYA & TOPAZ-1
Slide 45: TOPAZ-1 has the potential to become the first-ever IO therapy
TOPAZ-1 has the potential to become the first-ever IO therapy available for first-line, advanced biliary tract cancer patients Lack of innovation in biliary tract cancer TOPAZ-1 has practice-changing potential 10+ years • Trial stopped early at an interim analysis due to without innovation on top of
Slide 46: HIMALAYA – an innovative IO regimen delivering survival benefit
HIMALAYA – an innovative IO regimen delivering survival benefit to patients with advanced, unresectable hepatocellular carcinoma Large unmet need Innovative STRIDE regimen Clear efficacy, safety and in liver cancer with tremelimumab simplicity for patients 3rd • First IO+IO combination in first- lin
Slide 47: Liver cancer: HIMALAYA & TOPAZ-1 extending survival in hard-to-treat GI cancers
Liver cancer: HIMALAYA & TOPAZ-1 extending survival in hard-to-treat GI cancers Presenting with liver cancer Presenting with non-liver biliary tract carcinomas Other Hepato-cellular cancer Biliary tract carcinoma Liver Early Local/Locoregional stage diagnosis Advanced Stage, Drug treated BSC Stage A
Slide 48: DESTINY-Breast04
3 DESTINY-Breast04
Slide 49: Enhertu in breast cancer and beyond
Enhertu in breast cancer and beyond Opportunities across treatment settings neo-adjuvant / adjuvant 1st-line metastatic 2nd-line metastatic 3rd-line metastatic neo-adjuvant post neo-adjuvant adjuvant replace replace replace chemo + T-DM1 chemo + replace HER2-positive trastuzumab + trastuzumab + repl
Slide 50: Enhertu: an extensive clinical development programme
Enhertu: an extensive clinical development programme Focusing on HER2+ and HER2-low breast cancer and other cancers Post-neoadjuvant/ 1st line 2nd line 3rd line+ Adjuvant DESTINY-Breast05 Ph III DESTINY-Breast07 Ph Ib/II (Part 2) DESTINY-Breast03 Ph III DESTINY-Breast01 Ph II Breast cancer HER2+ DES
Slide 51: Breast cancer: well-positioned with at least six medicines
Breast cancer: well-positioned with at least six medicines Potential to cover most patients across settings and lines of treatment Early/curative setting Metastatic setting Neo-adjuvant Adjuvant 1st line 2nd line 3rd line 3rd line+ HER2+ Enhertu monotherapy Enhertu monotherapy c.20% of patients and
Slide 52: DESTINY-Breast04
DESTINY-Breast04 3L HER2-low mBC in the US Chemo naïve ~65% Prior Chemo ~35% DB04 4L+ HER2-low mBC in the US DB04 population equates to a Message 1 treated patient population of around half all 3L+ patients Chemo naïve ~35% Message Prior Chemo ~65% 2 DB06 includes chemo naïve patients in 2L/3L+ 52 D
Slide 53: Use of AstraZeneca slides from conference calls and webcasts
Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to th